Pliant Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Pliant Therapeutics

08/08/2025 05:08

Pliant Therapeutics Inc PLRX.OQ reported a quarterly adjusted loss of 71 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -92 cents.  The mean expectation of thirteen analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from $-1.09 to -48 cents per share.

Reported revenue was zero​; analysts expected zero.

Pliant Therapeutics Inc's reported EPS for the quarter was a loss of 71 cents​.

The company reported a quarterly loss of $43.3 million.

Pliant Therapeutics Inc shares had risen by 45.7% this quarter and lost 87.2% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 8.9% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 11 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."

Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00, about 44% above its last closing price of $1.68

This summary was machine generated from LSEG data August 8 at 04:07 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.70
-0.71
Missed
Mar. 31 2025
-0.72
-0.92
Missed
Dec. 31 2024
-0.98
-0.82
Beat
Sep. 30 2024
-0.97
-0.95
Beat